You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

stage I marginal zone lymphoma

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Indolent

Completed
Has Results
  • Ann Arbor Stage III Grade 1 Follicular Lymphoma
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 28, 2021

Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in Miami (Acalabrutinib,

Terminated
Has Results
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Miami, Florida
    University of Miami
Aug 23, 2022

Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

Not yet recruiting
  • Non-hodgkin Lymphoma
  • +9 more
  • CD79b-19 CAR T cells
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 6, 2023

MALT Lymphoma Trial in France, Italy, Switzerland (Chlorambucil, Rituximab i.v., Rituximab s.c.)

Active, not recruiting
  • MALT Lymphoma
  • Créteil, France
  • +37 more
Nov 4, 2022

Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, MDS Trial in Tucson (Bendamustine, Cyclophosphamide)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +12 more
  • Tucson, Arizona
    The University of Arizona Cancer Center
Dec 13, 2022

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Palo Alto (Ibrutinib, Radiation

Active, not recruiting
  • Grade 1 Follicular Lymphoma
  • +6 more
  • Palo Alto, California
    Stanford University, School of Medicine
Jun 13, 2022

Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Large B-Cell, Diffuse Trial in Spain (Registry of

Recruiting
  • Lymphoma, T-Cell, Cutaneous
  • +5 more
  • Registry of patients (exposure is Cutaneous Lymphoma)
  • Barcelona, Spain
  • +13 more
Mar 15, 2022

(CHANT)Real World Study of Duvelisib in Treatment of

Not yet recruiting
  • Follicular Lymphoma
  • +5 more
  • (no location specified)
Jun 20, 2023

Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Seattle (Laboratory Biomarker

Active, not recruiting
Has Results
  • Follicular Lymphoma
  • +2 more
  • Laboratory Biomarker Analysis
  • Pembrolizumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 6, 2022

Marginal Zone Lymphoma Trial in Zhengzhou (Bortezomib, Rituximab, Epirubicin)

Recruiting
  • Marginal Zone Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Aug 15, 2021

Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL Trial in Australia, Korea, Republic of, United States (IGM-2323)

Recruiting
  • Non-Hodgkin Lymphoma
  • +4 more
  • Duarte, California
  • +23 more
Dec 28, 2022

Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia Trial in Worldwide (Iopofosine I 131 single dose,

Recruiting
  • Waldenstrom Macroglobulinemia
  • +8 more
  • Iopofosine I 131 single dose
  • +2 more
  • Redlands, California
  • +42 more
Dec 30, 2022

Marginal Zone Lymphoma, Follicular Lymphoma, DLBCL Trial in China (Zanubrutinib, Rituximab)

Completed
Has Results
  • Marginal Zone Lymphoma
  • +2 more
  • Harbin, Heilongjiang, China
  • +3 more
Oct 26, 2021

Marginal Zone Lymphoma Trial in Austria, Italy, Switzerland (Tafasitamab, Acalabrutinib)

Recruiting
  • Marginal Zone Lymphoma
  • Wien, Austria
  • +9 more
Jul 13, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +20 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 11, 2022

Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL) Trial in Milwaukee (8/12-Day

Recruiting
  • Non Hodgkin Lymphoma (NHL)
  • +6 more
  • 8/12-Day Production of Car-T Cells
  • +2 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin and Froedtert Hospital
Jul 1, 2022

Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor

Recruiting
  • Non-Hodgkin's Lymphoma
  • +18 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Mar 11, 2021

Mature B-Cell Tumor, Non Hodgkin Lymphoma, DLBCL Trial (SGR-1505)

Not yet recruiting
  • Mature B-Cell Neoplasm
  • +25 more
  • (no location specified)
Sep 14, 2022

Marginal Zone B-cell Lymphoma Trial in Korea, Republic of (bendamustine plus rituximab)

Completed
  • Marginal Zone B-cell Lymphoma
  • bendamustine plus rituximab
  • Jeonju, Jeollabuk-do, Korea, Republic of
  • +10 more
Sep 23, 2021

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma Trial in United States (Zilovertamab vedotin)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +11 more
  • Zilovertamab vedotin
  • Duarte, California
  • +13 more
Jan 12, 2023

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
Has Results
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +20 more
  • Scottsdale, Arizona
  • +1 more
May 6, 2022

Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial (Routine care as per

Not yet recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +5 more
  • Routine care as per site standard.
  • (no location specified)
Sep 15, 2023

Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Seattle (Nivolumab)

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +17 more
  • Nivolumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 16, 2022

Follicular Lymphoma and Marginal Zone Lymphoma Trial in Beijing (Recombinant Humanized Monoclonal Antibody MIL62 Injection,

Recruiting
  • Follicular Lymphoma and Marginal Zone Lymphoma
  • Recombinant Humanized Monoclonal Antibody MIL62 Injection
  • Lenalidomide
  • Beijing, China
    Chinese Academy of Medical Sciences and Peking Union Medical Col
Jun 15, 2021

Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Marginal Zone Lymphoma Trial in France (Atezolizumab, Obinutuzumab,

Completed
  • Follicular Lymphoma
  • +3 more
  • Angers, France
  • +24 more
Jan 9, 2023